Xintela AB

1XT

Company Profile

  • Business description

    Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.

  • Contact

    Medicon Village
    Lund22381
    SWE

    T: +46 462756500

    https://www.xintela.se

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    13

Stocks News & Analysis

stocks

Earnings from our top global lithium pick

Shares rise on improved free cash flow generation.
stocks

After slump this ASX share may be an opportunity

Lower than expected guidance led to a sell-off.
stocks

Investment decisions in overvalued bank drive strong results

Shares fall despite a broadly unchanged outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,109.4052.500.58%
CAC 408,055.51105.331.32%
DAX 4023,959.99390.031.65%
Dow JONES (US)47,353.85366.750.78%
FTSE 1009,787.15104.581.08%
HKSE26,649.06407.231.55%
NASDAQ23,524.25519.712.26%
Nikkei 22550,911.76635.391.26%
NZX 50 Index13,617.4818.270.13%
S&P 5006,829.74100.941.50%
S&P/ASX 2008,835.9044.100.50%
SSE Composite Index4,018.6021.040.53%

Market Movers